The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
Why Hire an Experienced CMC Consultant for Your Early Phase Studies
Read More
webinar
Formulation and Analytical Considerations for Preclinical and Early Phase Pharmaceutical Development
Read More
post
Components of a Successful Regulatory Strategy for Drug Development
Read More
post
The Complete Regulatory Pathway for Medical Devices: From Concept to Market
Read More
Let's move from science to success.
Let’s Talk